GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3290)

  • GC90659 structure
    GC906596-epi COTC
    CAS: 959150-61-9
    Purity: >90.00%

    مشتق من COTC له نشاط مضاد للسرطان

  • GC90883 structure
    GC90883Purine riboside-5'-O-triphosphate (sodium salt)
    CAS: 35892-95-6
    Purity: >95.00%

    متابوليت نبولارين النشط.

  • GC90886 structure
    GC90886SZM-1209
    CAS: 2919801-86-6
    Purity: >98.00%

    مثبط لـ RIPK1

  • GC90889 structure
    GC908895-(3'-Hydroxyphenyl)-γ-Valerolactone
    CAS: 21618-91-7
    Purity: >95.00%

    متابوليت من مختلف البوليفينولات

  • GC91028 structure
    GC91028L-K6L9 (trifluoroacetate salt)
    Purity: >98.00%

    ببتيد سايتوليتيك.

  • GC91040 structure
    GC91040AP-1
    Purity: >95.00%

    بروتاك يدفع تحلل ALK

  • GC91049 structure
    GC91049Iturin A-2
    CAS: 83785-07-3
    Purity: >90.00%

    ليبوببتيد دائري ذو أنشطة حيوية متنوعة

  • GC91060 structure
    GC91060Ferritin PROTAC DeFer-2
    Purity: >98.00%

    بروتاك يدفع تحلل الفيريتين

  • GC91088 structure
    GC91088AMX12006
    CAS: 2639775-01-0
    Purity: >98.00%

    مثبط مستقبل EP4

  • GC91096 structure
    GC91096S-72
    CAS: 2446799-14-8
    Purity: >98.00%

    مثبط لتكثيف الأنابيب الدقيقة.

  • GC91113 structure
    GC91113A011
    Purity: >95.00%

    مثبط لإنزيم ATM كيناز

  • GC91154 structure
    GC9115433-BCRP Inhibitor
    Purity: >98.00%

    مثبط لـ BCRP

  • GC91162 structure
    GC91162Glucosamine Cholesterol
    CAS: 1257309-90-2
    Purity: >95.00%

    مركب ليبيدي يعتمد على الجلوكوزامين

  • GC91176 structure
    GC91176AOH1996
    CAS: 2089314-64-5
    Purity: >99.00%

    مثبط لبروتين PCNA

  • GC91208 structure
    GC91208Spiroxamine-d4
    CAS: 2469272-82-8
    Purity: >99.00%

    معيار داخلي لتحديد كمية السبيروكسامين

  • GC91228 structure
    GC91228SSE1806
    Purity: >95.00%

    مُنَحِّل الأنبوبات الدقيقة.

  • GC91297 structure
    GC91297Cholesterol-Doxorubicin
    Purity: >95.00%

    نموذج من البرودروغ لدوكسوروبيسين

  • GC91298 structure
    GC91298(±)-Linalool-d3
    CAS: 1216673-02-7
    Purity: >99.00%

    معيار داخلي لتحديد كمية (±)-linalool

  • GC91360 structure
    GC91360NM-3
    CAS: 181427-78-1
    Purity: >98.00%

    NM-3 هو إيزوكومارين اصطناعي ومثبط للأنغيوجينيز.

  • GC91403 structure
    GC91403HR68
    CAS: 2454582-64-8
    Purity: >98.00%

    HR68 هو عامل مضاد للسرطان ومشتق من محفز مستقبلات تكاثر الأجهزة الداخلية (PPAR) المعروف باسم حمض فينوفيبريك.

  • GC91427 structure
    GC91427Glutaminase C Inhibitor 11
    Purity: >95.00%

    مثبط الجلوتاميناز سي 11 هو مثبط لإنزيم الجلوتاميناز سي (GAC).

  • GC91595 structure
    GC91595PDIC-NC
    CAS: 2633013-75-7
    Purity: >95.00%

    PDIC-NC is an activator of stimulator of interferon genes (STING) and an anticancer agent.

  • GC91688 structure
    GC91688PDIC-NN
    CAS: 932740-48-2
    Purity: >95.00%

    PDIC-NN is an intermediate in the synthesis of PDIC-NS , an activator of stimulator of interferon genes (STING) with anticancer activity.

  • GC91782 structure
    GC91782DPP-9 Inhibitor 42
    Purity: >95.00%

    DPP-9 inhibitor 42 is an inhibitor of dipeptidyl peptidase 9 (DDP-9; IC50 = 0.0034 µM).